Total Funding
79
11
Total FundingDebt Financing raised
Growth Score
-6 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
1031842
Sirtris Pharmaceuticals develops small molecule drugs for the treatment of aging and metabolic diseases.
Acquired by 
GlaxoSmithKline
Paul Schimmel: Co-FounderPast Role: Massachusetts Institute of Technology, John D. and Catherine T. MacArthur Professor of Biophysics and Biochemistry
Larry Bock: Seed InvestorPast Role: Illumina, Co-Founder
GlaxoSmithKline
About the Company
Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes.
via: Sirtris
